Jefferies raised the firm’s price target on LivaNova to $90 from $82 and keeps a Buy rating on the shares following quarterly results. The firm remains encouraged by the momentum in LivaNova’s base business and likes the pipeline optionality, leading to favorable risk/reward and potential upside. As a reminder, LivaNova is winding down its ACS business to increase focus on the core, says Jefferies.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LIVN:
- LivaNova Refocuses Structure, Integrates Circulatory Support
- LivaNova announces Ahmet Tezel as chief innovation officer
- LivaNova jumps nearly 12% after saying trial likely to meet primary endpoint
- LivaNova reports positive predictive outcome for OSPREY trial for OSA
- LivaNova management to meet with Jefferies
